BioSpace News Archive

The International Gaucher Alliance (IGA) and Kantar Health announce today the launch of the disease registry GARDIAN: Gaucher Registry for Development Innovation and Analysis of Neuronopathic Disease.

TriSalus Life Sciences®, an emerging immuno-oncology company committed to transforming outcomes for patients with liver and pancreatic tumors, today announced data presented at the American Association of Cancer Research showing that regional delivery of oligodeoxynucleotide 2395 (ODN2395) activated the toll-like receptor 9 (TLR9), resulting in reduced tumor burden of liver metastases in mice.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company’s defensin-mimetic drug candidate, was featured in the “Mason Science Series: Rising to the National and International COVID-19 Challenge,” a presentation of George Mason University.

Today, three leading synthetic biology companies announced the launch of the Synthetic Biology (SynBio) Coalition (www.synbioco.com) to promote investment and support for the American synthetic biology industry. Synthetic biology is a field of science that involves redesigning microorganisms for useful purposes.

Life Biosciences, a pioneering life sciences company targeting the biology of aging, today announced that Joan Mannick , MD, Head of Research and Development, will participate in the 5 th Stanford Drug Discovery Symposium (SDDS 2021) being held virtually on April 19-20, 2021 .

Kintor Pharmaceutical Limited (stock code 9939.HK, “Kintor Pharmaceutical” or the “Company”), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, recently announced a strategic partnership with Hainan Visum Pharmaceutical Limited (“Visum”) to expand proxalutamide manufacturing.

Katena Products, Inc. (Katena) a leading global provider of premium ophthalmic instruments, biologics, and devices to hospitals, surgical centers, and ophthalmic and optometric offices announces the purchase of ASICO, LLC (ASICO).

Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and treat aging and age-related diseases, announces a publication

Open-label, non-randomized, controlled study will span one year and evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at root cause of type 2 diabetes Study to evaluate the durability of treatment effect and total cost of care impact of BT-001 in a diverse, real-world clinical setting with topline primary endpoint data expected in 2H 2022

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and cedazuridine (100 mg).